Citigroup Maintains Buy Rating on Evolent Health, Lowers PT to $4

jueves, 26 de febrero de 2026, 3:37 pm ET1 min de lectura
C--
EVH--

Citigroup Maintains Buy Rating on Evolent Health, Lowers PT to $4

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios